- No strong opportunity cluster is confirmed yet; monitor trend and activity pressure.
NGEN
NASDAQ
Week ended 07 Aug 2026
Weekly Investor Report
NervGen Pharma Corp. · Healthcare · Biotechnology
Latest close
1.71 USD
5.6%
latest week
Weekly setup
Weak trend
The weekly trend is not active. Price is -46.8% below the Trend Line and sits at 2.8% of its 52-week range. The latest completed week returned 5.6%, after a -9.0% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. Options positioning is volatility with 54/100 conviction, while the latest news-sentiment score is 50/100. Near-term considerations: volume confirmation is below normal; earnings are due in 8d.
Setup score
19
out of 100
Latest Close
1.71 USD
7 Aug 2026
1W Return
5.6%
latest completed week
4W Return
-9.0%
short-term follow-through
12W Return
-52.0%
quarterly tape
Trend Breadth
0.0%
0 of 31 weeks active
Volume Ratio
0.4x
vs 13-week average
- The trend backdrop is inactive, so price action has not confirmed a constructive regime.
- Price is below the Trend Line, which keeps downside pressure in focus.
- Price is below Fair Value, so the market is still discounting the latest tape.
- Activity pressure is negative, which weakens the current setup.
- Trend Line remains the key weekly regime level.
- Activity pressure is the gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through
5.6%
Latest completed week; four-week move -9.0%.
Indicator stack
0/32
Trend and activity pressure are weighted against the latest 12-week confirmation window.
Trend backdrop
Active
The trend backdrop defines the current weekly regime.
Patient Capital
Quiet
Activity-pressure buy-signal status for institutional accumulation timing.
Next-Week Expectancy
Negative 30.85%
Historical one-week expectancy contributes to the evidence score when direction is confirmed.
Options pressure
Volatility
54/100 conviction; expected move 62.9%.
News sentiment
50/100
40 relevant articles in the latest sentiment read.
Event risk
8d
Next report is scheduled for 21 Aug 2026; event risk rises as the date approaches.
01 · Price action
Study the full chart
Where price is—and whether the trend supports it
The weekly trend is not active. Price is -46.8% below the Trend Line and sits at 2.8% of its 52-week range. The latest completed week returned 5.6%, after a -9.0% four-week move.
52-week price path
Price vs Trend Line and Fair Value
Price
Trend Line
Fair Value
02 · Volume and demand
Is real participation confirming the move?
Latest weekly volume is 0.4x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.
26-week volume confirmation
Bar height shows volume; colour shows the weekly price direction
13 Feb
20 Feb
27 Feb
6 Mar
13 Mar
20 Mar
27 Mar
3 Apr
10 Apr
17 Apr
24 Apr
1 May
8 May
15 May
22 May
29 May
5 Jun
12 Jun
19 Jun
26 Jun
3 Jul
10 Jul
17 Jul
24 Jul
31 Jul
7 Aug
Up week
Down week
Demand beneath price
Activity pressure and institutional-style signals
These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.
Activity pressure path
Latest 0.0112-week average 0.02
12-week confirmation
Trend active0/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure0/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership0/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.01Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers
No recent accumulation markers. No reversal markers.
03 · Momentum and leadership
Is performance persistent—and is the stock leading?
Performance is -9.0% over four weeks, -52.0% over 12 weeks, and - over one year. The current trend has remained active for 0 consecutive weeks.
Performance by holding period
Active trend streak0 weeks
Active weeks in one year0
Trend breadth0.0%
Activity pressure vs relative leadership
Activity pressureRelative leadership
Pressure-1.01Latest activity-pressure read.
Pressure change-Four-week change in activity pressure.
Leadership-Latest relative-leadership reading.
RS change-Four-week change in relative leadership.
04 · Fundamentals and valuation
Open full factor analysis
What investors are paying for—and the quality behind it
The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.
Factor week 09 Aug 2026
Financial statements through 31 Mar 2026
Field coverage 58%
Model confidence 54%
Relative factor standing
Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.
Overall factor strength51/100Blend of value, momentum, and quality. Underlying universe rank 50; rank 1 is best.
Value50/100Relative valuation strength. Underlying universe rank 51; rank 1 is best.
Quality47/100Profitability and accounting quality. Underlying universe rank 54; rank 1 is best.
Momentum49/100Medium-term price momentum. Underlying universe rank 52; rank 1 is best.
Growth50/100Revenue and earnings growth. Underlying universe rank 51; rank 1 is best.
Quality and valuation are separate questions
A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.
Valuation
How much investors are paying for earnings, sales, and cash flow.
- P/E
- - Price divided by trailing earnings.
- Price / sales
- - Market value relative to trailing revenue.
- EV / EBITDA
- - Enterprise value relative to operating cash earnings.
- Free-cash-flow yield
- -16.6% Free cash flow as a share of enterprise value.
Business quality
Margins and the return generated on invested capital.
- Gross margin
- - Gross profit retained from each unit of revenue.
- Operating margin
- - Operating profit retained from revenue.
- Free-cash-flow margin
- - Free cash flow generated from revenue.
- Return on invested capital
- - Operating return generated on invested capital.
Growth and financial strength
Recent business growth and accounting strength.
- Revenue growth
- - Latest one-year revenue growth.
- EPS growth
- - Latest one-year earnings-per-share growth.
- Free-cash-flow growth
- - Latest one-year free-cash-flow growth.
- Piotroski F-score
- 3/9 Nine-point accounting-strength checklist.
Shareholder return and balance sheet
Cash returned to owners and financial leverage.
- Dividend yield
- - Cash dividends relative to market value.
- Buyback yield
- -9.3% Net share repurchases relative to market value.
- Shareholder yield
- -9.3% Dividend yield plus net buyback yield.
- Net debt / EBITDA
- 2.0x Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment
What other market participants are doing
Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.
Options positioningVolatility
NGEN shows volatility options pressure with a 54/100 conviction score, put-call volume ratio of 0.00, expected move of 62.9%, and Sharemaestro trend signal inactive.
Conviction54/100
Expected move62.9%
Put/call volume0.00
Insider activity-
No recent insider transactions are stored for this company.
News sentiment50/100
Weighted news tone is neutral across 40 relevant articles.
5 positive · 31 neutral · 4 negativePatient CapitalQuiet
Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal
06 · Catalysts and risk
What can move the shares—and how volatile the path has been
Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.
Next earnings8dNext report is scheduled for 21 Aug 2026; event risk rises as the date approaches.
Options expected move62.9%Nearest-chain priced movement where available.
52-week drawdown-72.9%Distance below the 52-week high.
13-week volatility13.8%Standard deviation of weekly returns.
Weekly gains and losses
Latest 26 completed weeksEach bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.
13 Feb
13 Mar
10 Apr
8 May
5 Jun
3 Jul
7 Aug
Weeks higher10 of 2616 weeks finished lower.
Best week+16.4%Week of 3 Apr.
Worst week-41.7%Week of 22 May.
Latest week+5.6%Week of 7 Aug.
Shape of recent returns
Strong gains7
Modest gains3
Flat weeks0
Modest losses6
Sharp losses10
Recent vol13.8%13-week weekly-return volatility.
Base vol11.3%52-week weekly-return volatility.
Up/down split10/20Count of positive and negative weeks in the 52-week window.
Average skew7.9% / -8.8%Average positive week versus average negative week.
07 · Sector and peer context
Is this stock leading—or simply moving with its group?
Sector and industry breadth distinguish company-specific strength from a broad group move.
SectorUS Healthcare
4-week rank- / 100
Group average2.6%
Trend breadth54.0%
Trend54.0%active weekly trend signals
MD77.0%positive activity pressure
RS44.0%positive relative leadership
Four-week leaders
IndustryUS Biotechnology
4-week rank- / 100
Group average0.5%
Trend breadth70.0%
Trend70.0%active weekly trend signals
MD64.0%positive activity pressure
RS62.0%positive relative leadership
Four-week leaders
08 · Evidence and weekly data
The underlying research record
Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.
Weekly tape21/100
Trend, activity pressure, participation, and risk combine to a 21/100 tape read.
Indicator analysis9/100Latest 12-week confirmation: trend 0/12, activity pressure 0/12, relative leadership 0/12.
Activity pressure 0.01; No reversal markers Next-Week ExpectancyNegative 30.85%Next-week expectancy is negative with a 30.85% historical one-week setup read.
Adds short-term historical context without overriding trend, activity, or relative leadership. Factors48/100O'Shaughnessy factor stack blends value, quality, momentum, and confidence.
Buyback Yield rank 86; Small Cap Core rank 54 Patient CapitalQuietActivity-pressure buy-signal evidence highlights potential institutional accumulation windows.
No recent buy signal Options36/100NGEN shows volatility options pressure with a 54/100 conviction score, put-call volume ratio of 0.00, expected move of 62.9%, and Sharemaestro trend signal inactive.
Volatility · Volatility expansion watch · Expected move 62.9% Sentiment50/100Weighted news tone is neutral across 40 relevant articles.
NGEN|Nervgen Pharma Ord Shs|Price:1.620|Chg%:+0.020 Insiders50/100No recent insider transaction evidence is stored.
Earnings8dNext report is scheduled for 21 Aug 2026; event risk rises as the date approaches.
| Week | Close | Return | Trend Line | Fair Value | Pressure | Leadership | Volume | Trend |
|---|---|---|---|---|---|---|---|---|
| 7 Aug 2026 | 1.71 USD | 5.6% | 3.21 USD | 3.30 USD | -1.01 | - | 1.8M | Off |
| 31 Jul 2026 | 1.62 USD | -0.6% | 3.35 USD | 3.35 USD | -1.11 | - | 1.6M | Off |
| 24 Jul 2026 | 1.63 USD | -2.4% | - | 3.41 USD | -0.83 | - | 2.7M | Off |
| 17 Jul 2026 | 1.67 USD | -11.2% | - | 3.47 USD | - | - | 6.1M | Off |
| 10 Jul 2026 | 1.88 USD | -11.3% | - | 3.54 USD | - | - | 3.8M | Off |
| 3 Jul 2026 | 2.12 USD | 13.4% | - | 3.60 USD | - | - | 2.9M | Off |
| 26 Jun 2026 | 1.87 USD | -15.0% | - | 3.66 USD | - | - | 4.0M | Off |
| 19 Jun 2026 | 2.20 USD | 14.6% | - | 3.74 USD | - | - | 4.3M | Off |
| 12 Jun 2026 | 1.92 USD | 3.2% | - | 3.80 USD | 0.00 | - | 3.7M | Off |
| 5 Jun 2026 | 1.86 USD | -10.1% | - | 3.89 USD | 0.00 | - | 5.2M | Off |
| 29 May 2026 | 2.07 USD | -0.5% | - | 3.98 USD | 0.00 | - | 9.4M | Off |
| 22 May 2026 | 2.08 USD | -41.7% | - | 4.08 USD | 0.00 | - | 13.4M | Off |
| 15 May 2026 | 3.56 USD | -4.9% | - | 4.19 USD | 0.00 | - | 1.0M | Off |
| 8 May 2026 | 3.75 USD | -0.8% | - | 4.22 USD | 0.00 | - | 723.4K | Off |
How to use this report
This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.